512 related articles for article (PubMed ID: 28831825)
41. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
Min Lee CK; Li S; Tran DC; Zhu GA; Kim J; Kwong BY; Chang ALS
J Am Acad Dermatol; 2018 Dec; 79(6):1047-1052. PubMed ID: 29857011
[TBL] [Abstract][Full Text] [Related]
42. Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy.
Pérez-Ruiz E; Etxeberria I; Rodriguez-Ruiz ME; Melero I
Clin Cancer Res; 2017 Sep; 23(18):5326-5328. PubMed ID: 28790118
[TBL] [Abstract][Full Text] [Related]
43. In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1.
Zhai W; Zhou X; Du J; Gao Y
Methods Enzymol; 2019; 629():361-381. PubMed ID: 31727249
[TBL] [Abstract][Full Text] [Related]
44. Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment.
Botticelli A; Zizzari I; Mazzuca F; Ascierto PA; Putignani L; Marchetti L; Napoletano C; Nuti M; Marchetti P
Oncotarget; 2017 Jan; 8(5):8890-8899. PubMed ID: 27806346
[TBL] [Abstract][Full Text] [Related]
45. Could PD-1/PDL1 immune checkpoints be linked to HLA signature?
Correale P; Saladino RE; Nardone V; Giannicola R; Agostino R; Pirtoli L; Caraglia M; Botta C; Tagliaferri P
Immunotherapy; 2019 Dec; 11(18):1523-1526. PubMed ID: 31865873
[No Abstract] [Full Text] [Related]
46. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.
Johnson DB; Frampton GM; Rioth MJ; Yusko E; Xu Y; Guo X; Ennis RC; Fabrizio D; Chalmers ZR; Greenbowe J; Ali SM; Balasubramanian S; Sun JX; He Y; Frederick DT; Puzanov I; Balko JM; Cates JM; Ross JS; Sanders C; Robins H; Shyr Y; Miller VA; Stephens PJ; Sullivan RJ; Sosman JA; Lovly CM
Cancer Immunol Res; 2016 Nov; 4(11):959-967. PubMed ID: 27671167
[TBL] [Abstract][Full Text] [Related]
47. Checkpoint inhibitors: outstanding efficacy but at what cost?
Klastersky JA
Curr Opin Oncol; 2016 Jul; 28(4):253. PubMed ID: 27163724
[No Abstract] [Full Text] [Related]
48. Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy.
Novotny JF; Cogswell J; Inzunza H; Harbison C; Horak C; Averbuch S
Ann Oncol; 2016 Oct; 27(10):1966-9. PubMed ID: 27502705
[TBL] [Abstract][Full Text] [Related]
49. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H
Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553
[TBL] [Abstract][Full Text] [Related]
50. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
[TBL] [Abstract][Full Text] [Related]
51. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.
Teng F; Meng X; Kong L; Yu J
Cancer Lett; 2018 Feb; 414():166-173. PubMed ID: 29155348
[TBL] [Abstract][Full Text] [Related]
52. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
[TBL] [Abstract][Full Text] [Related]
53. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
[TBL] [Abstract][Full Text] [Related]
54. [Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma].
Adam J; Tomasic G; Robert C
Ann Pathol; 2017 Feb; 37(1):55-60. PubMed ID: 28111041
[TBL] [Abstract][Full Text] [Related]
55. Immune signatures predicting responses to immunomodulatory antibody therapy.
Pawelec G
Curr Opin Immunol; 2018 Apr; 51():91-96. PubMed ID: 29550661
[TBL] [Abstract][Full Text] [Related]
56. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.
Yi M; Jiao D; Xu H; Liu Q; Zhao W; Han X; Wu K
Mol Cancer; 2018 Aug; 17(1):129. PubMed ID: 30139382
[TBL] [Abstract][Full Text] [Related]
57. Firing Up Cold Tumors.
Cheng WC; Ho PC
Trends Cancer; 2019 Sep; 5(9):528-530. PubMed ID: 31474357
[TBL] [Abstract][Full Text] [Related]
58. Therapeutic Potential of Checkpoint Inhibitors in Refractory Plasmablastic Lymphoma.
Damlaj M; Alzayed M; Alahmari B; Alhejazi A; Alaskar A; Alzahrani M
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):e559-e563. PubMed ID: 31377210
[No Abstract] [Full Text] [Related]
59. Combining Chemotherapy and Immunotherapy for the Treatment of Triple-Negative Breast Cancer.
McArthur H
Oncology (Williston Park); 2019 Apr; 33(4):137-40. PubMed ID: 30990566
[No Abstract] [Full Text] [Related]
60. Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy.
Makuku R; Khalili N; Razi S; Keshavarz-Fathi M; Rezaei N
J Immunol Res; 2021; 2021():6661406. PubMed ID: 33681388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
